tiprankstipranks
Trending News
More News >
Milestone Pharmaceuticals (MIST)
NASDAQ:MIST
US Market
Advertisement

Milestone Pharmaceuticals (MIST) Stock Forecast & Price Target

Compare
630 Followers
See the Price Targets and Ratings of:

MIST Analyst Ratings

Moderate Buy
3Ratings
Moderate Buy
2 Buy
1 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Milestone
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MIST Stock 12 Month Forecast

Average Price Target

$4.50
▲(148.62% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Milestone Pharmaceuticals in the last 3 months. The average price target is $4.50 with a high forecast of $5.00 and a low forecast of $4.00. The average price target represents a 148.62% change from the last price of $1.81.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","-1":"-$1","0.75":"$0.75","2.5":"$2.5","4.25":"$4.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.75,2.5,4.25,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.43,1.7046153846153846,1.9792307692307691,2.253846153846154,2.5284615384615385,2.8030769230769232,3.077692307692308,3.3523076923076927,3.6269230769230774,3.901538461538462,4.176153846153847,4.4507692307692315,4.725384615384615,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.43,1.666153846153846,1.9023076923076923,2.1384615384615384,2.374615384615385,2.6107692307692307,2.846923076923077,3.0830769230769235,3.3192307692307694,3.5553846153846154,3.7915384615384617,4.027692307692308,4.2638461538461545,{"y":4.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.43,1.6276923076923078,1.8253846153846154,2.023076923076923,2.220769230769231,2.4184615384615387,2.6161538461538463,2.8138461538461543,3.0115384615384615,3.2092307692307696,3.406923076923077,3.6046153846153848,3.802307692307693,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.34,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$5.00Average Price Target$4.50Lowest Price Target$4.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen Analyst forecast on MIST
TD Cowen
TD Cowen
Hold
Reiterated
08/14/25
TD Cowen Keeps Their Hold Rating on Milestone Pharmaceuticals (MIST)We think MIST likely could have more visibility into timing to corporate breakeven after both tranches are exercised. Etripamil pSVT NDA 2025, MIST announced the FDA accepted their response to the CMC issues raised in the etripamil CRL. The agency assigned a new PDUFA date of Dec 13, 2025. Importantly, the FDA did not raise any concerns regarding the clinical package of the etripamil NDA.
H.C. Wainwright Analyst forecast on MIST
H.C. Wainwright
H.C. Wainwright
$5
Buy
176.24%
Upside
Reiterated
08/12/25
Milestone Pharmaceuticals: Strong Buy Rating Backed by Anticipated Cardamyst Approval and Robust Financial PositionOur Buy rating and $5 price target are based on a risk-adjusted net present value analysis of Cardamyst’s potential in PSVT and AFib-RVR, using a discounted cash flow (DCF) model. We apply a weighted average cost of capital (WACC) of 12.2% and an exit multiple of 15.5x on our 2031 forecasts. We assign a 60% probability of success for PSVT and 25% for AFib-RVR. We remain confident in Cardamyst’s commercial potential, particularly in PSVT, where we project peak U.S. sales of approximately $511M ($306M risk adjusted) and AFib-RVR risk adjusted sales of $71M at peak currently.
Piper Sandler Analyst forecast on MIST
Piper Sandler
Piper Sandler
$4
Buy
120.99%
Upside
Reiterated
07/16/25
Analysts Offer Insights on Healthcare Companies: Kestra Medical Technologies Ltd. (NASDAQ: KMTS) and Milestone Pharmaceuticals (NASDAQ: MIST)
TR | OpenAI - 4o Analyst forecast on MIST
TR | OpenAI - 4o
TR | OpenAI - 4o
Sell
Reiterated
04/22/25
AI Generated ArticleAI Generated Article
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen Analyst forecast on MIST
TD Cowen
TD Cowen
Hold
Reiterated
08/14/25
TD Cowen Keeps Their Hold Rating on Milestone Pharmaceuticals (MIST)We think MIST likely could have more visibility into timing to corporate breakeven after both tranches are exercised. Etripamil pSVT NDA 2025, MIST announced the FDA accepted their response to the CMC issues raised in the etripamil CRL. The agency assigned a new PDUFA date of Dec 13, 2025. Importantly, the FDA did not raise any concerns regarding the clinical package of the etripamil NDA.
H.C. Wainwright Analyst forecast on MIST
H.C. Wainwright
H.C. Wainwright
$5
Buy
176.24%
Upside
Reiterated
08/12/25
Milestone Pharmaceuticals: Strong Buy Rating Backed by Anticipated Cardamyst Approval and Robust Financial PositionOur Buy rating and $5 price target are based on a risk-adjusted net present value analysis of Cardamyst’s potential in PSVT and AFib-RVR, using a discounted cash flow (DCF) model. We apply a weighted average cost of capital (WACC) of 12.2% and an exit multiple of 15.5x on our 2031 forecasts. We assign a 60% probability of success for PSVT and 25% for AFib-RVR. We remain confident in Cardamyst’s commercial potential, particularly in PSVT, where we project peak U.S. sales of approximately $511M ($306M risk adjusted) and AFib-RVR risk adjusted sales of $71M at peak currently.
Piper Sandler Analyst forecast on MIST
Piper Sandler
Piper Sandler
$4
Buy
120.99%
Upside
Reiterated
07/16/25
Analysts Offer Insights on Healthcare Companies: Kestra Medical Technologies Ltd. (NASDAQ: KMTS) and Milestone Pharmaceuticals (NASDAQ: MIST)
TR | OpenAI - 4o Analyst forecast on MIST
TR | OpenAI - 4o
TR | OpenAI - 4o
Sell
Reiterated
04/22/25
AI Generated ArticleAI Generated Article
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Milestone Pharmaceuticals

1 Month
xxx
Success Rate
7/13 ratings generated profit
54%
Average Return
+0.67%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.85% of your transactions generating a profit, with an average return of +0.67% per trade.
3 Months
xxx
Success Rate
6/13 ratings generated profit
46%
Average Return
-4.92%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 46.15% of your transactions generating a profit, with an average return of -4.92% per trade.
1 Year
Edward TenthoffPiper Sandler
Success Rate
4/13 ratings generated profit
31%
Average Return
-21.64%
reiterated a buy rating 2 months ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -21.64% per trade.
2 Years
xxx
Success Rate
4/13 ratings generated profit
31%
Average Return
-31.76%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 30.77% of your transactions generating a profit, with an average return of -31.76% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MIST Analyst Recommendation Trends

Rating
Mar 25
Apr 25
Jun 25
Jul 25
Aug 25
Strong Buy
7
7
6
5
5
Buy
0
0
0
0
0
Hold
6
7
8
4
3
Sell
1
2
2
1
0
Strong Sell
0
0
0
0
0
total
14
16
16
10
8
In the current month, MIST has received 5 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. MIST average Analyst price target in the past 3 months is 4.50.
Each month's total comprises the sum of three months' worth of ratings.

MIST Financial Forecast

MIST Earnings Forecast

Next quarter’s earnings estimate for MIST is -$0.16 with a range of -$0.20 to -$0.13. The previous quarter’s EPS was -$0.20. MIST beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.14% of the time in the same period. In the last calendar year MIST has Outperformed its overall industry.
Next quarter’s earnings estimate for MIST is -$0.16 with a range of -$0.20 to -$0.13. The previous quarter’s EPS was -$0.20. MIST beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.14% of the time in the same period. In the last calendar year MIST has Outperformed its overall industry.

MIST Sales Forecast

Next quarter’s sales forecast for MIST is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MIST beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.89% of the time in the same period. In the last calendar year MIST has Preformed in-line its overall industry.
Next quarter’s sales forecast for MIST is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MIST beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.89% of the time in the same period. In the last calendar year MIST has Preformed in-line its overall industry.

MIST Stock Forecast FAQ

What is MIST’s average 12-month price target, according to analysts?
Based on analyst ratings, Milestone Pharmaceuticals’s 12-month average price target is 4.50.
    What is MIST’s upside potential, based on the analysts’ average price target?
    Milestone Pharmaceuticals has 148.62% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MIST a Buy, Sell or Hold?
          Milestone Pharmaceuticals has a consensus rating of Moderate Buy which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Milestone Pharmaceuticals’s price target?
            The average price target for Milestone Pharmaceuticals is 4.50. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $5.00 ,the lowest forecast is $4.00. The average price target represents 148.62% Increase from the current price of $1.81.
              What do analysts say about Milestone Pharmaceuticals?
              Milestone Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of MIST?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis